GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Voyageur Pharmaceuticals Ltd (TSXV:VM) » Definitions » EPS (Diluted)

Voyageur Pharmaceuticals (TSXV:VM) EPS (Diluted) : C$-0.01 (TTM As of Feb. 2024)


View and export this data going back to 2012. Start your Free Trial

What is Voyageur Pharmaceuticals EPS (Diluted)?

Voyageur Pharmaceuticals's Earnings per Share (Diluted) for the three months ended in Feb. 2024 was C$-0.00. Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Feb. 2024 was C$-0.01.

Voyageur Pharmaceuticals's EPS (Basic) for the three months ended in Feb. 2024 was C$-0.00. Its EPS (Basic) for the trailing twelve months (TTM) ended in Feb. 2024 was C$-0.01.

Voyageur Pharmaceuticals's EPS without NRI for the three months ended in Feb. 2024 was C$-0.00. Its EPS without NRI for the trailing twelve months (TTM) ended in Feb. 2024 was C$-0.01.

During the past 3 years, the average EPS without NRIGrowth Rate was 17.80% per year. During the past 5 years, the average EPS without NRI Growth Rate was 0.50% per year. During the past 10 years, the average EPS without NRI Growth Rate was 4.60% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EPS without NRI Growth Rate using EPS without NRI data.

During the past 13 years, Voyageur Pharmaceuticals's highest 3-Year average EPS without NRI Growth Rate was 80.70% per year. The lowest was -152.00% per year. And the median was 19.20% per year.


Voyageur Pharmaceuticals EPS (Diluted) Historical Data

The historical data trend for Voyageur Pharmaceuticals's EPS (Diluted) can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Voyageur Pharmaceuticals EPS (Diluted) Chart

Voyageur Pharmaceuticals Annual Data
Trend Dec14 Dec15 Nov16 Nov17 Nov18 Nov19 Nov20 Nov21 Nov22 Nov23
EPS (Diluted)
Get a 7-Day Free Trial Premium Member Only Premium Member Only -0.01 -0.02 -0.02 -0.02 -0.01

Voyageur Pharmaceuticals Quarterly Data
May19 Aug19 Nov19 Feb20 May20 Aug20 Nov20 Feb21 May21 Aug21 Nov21 Feb22 May22 Aug22 Nov22 Feb23 May23 Aug23 Nov23 Feb24
EPS (Diluted) Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - -0.01 - - -

Competitive Comparison of Voyageur Pharmaceuticals's EPS (Diluted)

For the Drug Manufacturers - Specialty & Generic subindustry, Voyageur Pharmaceuticals's PE Ratio, along with its competitors' market caps and PE Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Voyageur Pharmaceuticals's PE Ratio Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Voyageur Pharmaceuticals's PE Ratio distribution charts can be found below:

* The bar in red indicates where Voyageur Pharmaceuticals's PE Ratio falls into.



Voyageur Pharmaceuticals EPS (Diluted) Calculation

EPS (Diluted) is a rough measurement of the amount of a company's profit that can be allocated to one share of its stock. Diluted EPS takes into account all of the outstanding dilutive securities that could potentially be exercised (such as stock options and convertible preferred stock) and shows how such an action would impact earnings per share.

Voyageur Pharmaceuticals's Diluted EPS for the fiscal year that ended in Nov. 2023 is calculated as

Diluted EPS (A: Nov. 2023 ) = (Net Income - Preferred Dividends) / Shares Outstanding (Diluted Average)
=(-1.399-0)/130.504
=-0.01

Voyageur Pharmaceuticals's Diluted EPS for the quarter that ended in Feb. 2024 is calculated as

Diluted EPS (Q: Feb. 2024 )=(Net Income - Preferred Dividends) / Shares Outstanding (Diluted Average)
=(-0.329-0)/132.737
=-0.00

EPS (Diluted) for the trailing twelve months (TTM) ended in Feb. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was C$-0.01

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Voyageur Pharmaceuticals  (TSXV:VM) EPS (Diluted) Explanation

EPS is the single most important variable used by Wall Street in determining the earnings power of a company. But investors need to be aware that Earnings per Share can be easily manipulated by adjusting depreciation and amortization rate or non-recurring items. That's why GuruFocus lists EPS without NRI, which better reflects the company's underlying performance.


Be Aware

Compared with Earnings per share, a company's cash flow is better indicator of the company's earnings power.

If a company's earnings per share is less than cash flow per share over long term, investors need to be cautious and find out why.


Voyageur Pharmaceuticals EPS (Diluted) Related Terms

Thank you for viewing the detailed overview of Voyageur Pharmaceuticals's EPS (Diluted) provided by GuruFocus.com. Please click on the following links to see related term pages.


Voyageur Pharmaceuticals (TSXV:VM) Business Description

Traded in Other Exchanges
Address
333 Southwest 7th Avenue, Suite 800, Calgary, AB, CAN, T2P 2Z1
Voyageur Pharmaceuticals Ltd is engaged in the development of pharmaceutical ingredients (API) minerals. The company focuses on developing barium and iodine radiocontrast products and bromine-based pharmaceutical products. It provides its products for medical applications and diagnostics.

Voyageur Pharmaceuticals (TSXV:VM) Headlines

No Headlines